Corcept Therapeutics Incorporated (0I3Q.L)
USD 72.67
(-1.2%)
USD 72.67
(-1.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -135.4 Million USD | 68.91% |
| 2022 | -435.47 Million USD | -29.88% |
| 2021 | -335.28 Million USD | 29.32% |
| 2020 | -474.34 Million USD | -52.1% |
| 2019 | -311.85 Million USD | -50.83% |
| 2018 | -206.76 Million USD | -98.76% |
| 2017 | -104.02 Million USD | -182.12% |
| 2016 | -36.87 Million USD | -44.77% |
| 2015 | -25.47 Million USD | -71.82% |
| 2014 | -14.82 Million USD | 69.83% |
| 2013 | -49.13 Million USD | 45.64% |
| 2012 | -90.38 Million USD | -128.04% |
| 2011 | -39.63 Million USD | -61.26% |
| 2010 | -24.57 Million USD | -3.0% |
| 2009 | -23.86 Million USD | -62.32% |
| 2008 | -14.7 Million USD | -28.9% |
| 2007 | -11.4 Million USD | -28.66% |
| 2006 | -8.86 Million USD | -135.62% |
| 2005 | -3.76 Million USD | 36.56% |
| 2004 | -5.93 Million USD | 37.9% |
| 2003 | -9.54 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -149.67 Million USD | -10.54% |
| 2024 Q3 | -130.49 Million USD | -6.17% |
| 2024 Q2 | -122.91 Million USD | 17.88% |
| 2023 FY | -135.4 Million USD | 68.91% |
| 2023 Q3 | -111.57 Million USD | 35.16% |
| 2023 Q4 | -135.4 Million USD | -21.35% |
| 2023 Q1 | -464.48 Million USD | -6.66% |
| 2023 Q2 | -172.08 Million USD | 62.95% |
| 2022 Q4 | -435.47 Million USD | -797.22% |
| 2022 Q1 | -59.04 Million USD | 82.39% |
| 2022 FY | -435.47 Million USD | -29.88% |
| 2022 Q2 | -379.71 Million USD | -543.08% |
| 2022 Q3 | -48.53 Million USD | 87.22% |
| 2021 FY | -335.28 Million USD | 29.32% |
| 2021 Q2 | -93.87 Million USD | -86.57% |
| 2021 Q1 | -50.31 Million USD | 89.39% |
| 2021 Q4 | -335.28 Million USD | -258.05% |
| 2021 Q3 | -93.64 Million USD | 0.24% |
| 2020 Q3 | -27.52 Million USD | 49.96% |
| 2020 Q1 | -345.89 Million USD | -10.92% |
| 2020 Q2 | -55.01 Million USD | 84.09% |
| 2020 Q4 | -474.34 Million USD | -1623.06% |
| 2020 FY | -474.34 Million USD | -52.1% |
| 2019 FY | -311.85 Million USD | -50.83% |
| 2019 Q2 | -224.55 Million USD | -366.57% |
| 2019 Q1 | -48.12 Million USD | 76.72% |
| 2019 Q3 | -44.17 Million USD | 80.33% |
| 2019 Q4 | -311.85 Million USD | -605.9% |
| 2018 Q1 | -140.37 Million USD | -34.94% |
| 2018 Q4 | -206.76 Million USD | -510.02% |
| 2018 Q3 | -33.89 Million USD | -8.76% |
| 2018 Q2 | -31.16 Million USD | 77.8% |
| 2018 FY | -206.76 Million USD | -98.76% |
| 2017 Q2 | -63.08 Million USD | -33.77% |
| 2017 FY | -104.02 Million USD | -182.12% |
| 2017 Q4 | -104.02 Million USD | -35.69% |
| 2017 Q3 | -76.66 Million USD | -21.52% |
| 2017 Q1 | -47.16 Million USD | -27.9% |
| 2016 Q3 | -29.14 Million USD | -49.53% |
| 2016 Q4 | -36.87 Million USD | -26.53% |
| 2016 Q1 | -24.42 Million USD | 4.11% |
| 2016 FY | -36.87 Million USD | -44.77% |
| 2016 Q2 | -19.48 Million USD | 20.2% |
| 2015 FY | -25.47 Million USD | -71.82% |
| 2015 Q3 | -22.94 Million USD | 8.28% |
| 2015 Q1 | -27.29 Million USD | -84.13% |
| 2015 Q4 | -25.47 Million USD | -11.01% |
| 2015 Q2 | -25.01 Million USD | 8.36% |
| 2014 Q2 | -26.57 Million USD | 27.62% |
| 2014 Q1 | -36.72 Million USD | 25.26% |
| 2014 FY | -14.82 Million USD | 69.83% |
| 2014 Q4 | -14.82 Million USD | 18.19% |
| 2014 Q3 | -18.11 Million USD | 31.83% |
| 2013 Q1 | -77.56 Million USD | 14.19% |
| 2013 FY | -49.13 Million USD | 45.64% |
| 2013 Q2 | -68.57 Million USD | 11.59% |
| 2013 Q3 | -58.67 Million USD | 14.43% |
| 2013 Q4 | -49.13 Million USD | 16.26% |
| 2012 FY | -90.38 Million USD | -128.04% |
| 2012 Q4 | -90.38 Million USD | -27.2% |
| 2012 Q3 | -71.05 Million USD | -103.6% |
| 2012 Q1 | -42.62 Million USD | -7.55% |
| 2012 Q2 | -34.89 Million USD | 18.13% |
| 2011 Q3 | -45.9 Million USD | 12.1% |
| 2011 FY | -39.63 Million USD | -61.26% |
| 2011 Q2 | -52.23 Million USD | 11.78% |
| 2011 Q1 | -59.2 Million USD | -140.87% |
| 2011 Q4 | -39.63 Million USD | 13.67% |
| 2010 Q3 | -29 Million USD | 18.04% |
| 2010 Q4 | -24.57 Million USD | 15.25% |
| 2010 Q2 | -35.38 Million USD | -90.82% |
| 2010 FY | -24.57 Million USD | -3.0% |
| 2010 Q1 | -18.54 Million USD | 22.28% |
| 2009 Q4 | -23.86 Million USD | -122.85% |
| 2009 Q1 | -19.18 Million USD | -30.48% |
| 2009 Q2 | -14.43 Million USD | 24.74% |
| 2009 Q3 | -10.7 Million USD | 25.83% |
| 2009 FY | -23.86 Million USD | -62.32% |
| 2008 Q2 | -26.1 Million USD | 17.83% |
| 2008 Q4 | -14.7 Million USD | 9.82% |
| 2008 Q3 | -16.3 Million USD | 37.54% |
| 2008 Q1 | -31.76 Million USD | -178.54% |
| 2008 FY | -14.7 Million USD | -28.9% |
| 2007 Q4 | -11.4 Million USD | 38.46% |
| 2007 FY | -11.4 Million USD | -28.66% |
| 2007 Q2 | -11.91 Million USD | 18.98% |
| 2007 Q3 | -18.53 Million USD | -55.55% |
| 2007 Q1 | -14.7 Million USD | -65.9% |
| 2006 Q2 | -3.77 Million USD | -81.21% |
| 2006 FY | -8.86 Million USD | -135.62% |
| 2006 Q3 | -3.25 Million USD | 13.79% |
| 2006 Q4 | -8.86 Million USD | -172.65% |
| 2006 Q1 | -2.08 Million USD | 44.68% |
| 2005 Q2 | -2.81 Million USD | 19.57% |
| 2005 Q3 | -1.36 Million USD | 51.46% |
| 2005 Q4 | -3.76 Million USD | -175.2% |
| 2005 Q1 | -3.5 Million USD | 40.96% |
| 2005 FY | -3.76 Million USD | 36.56% |
| 2004 Q1 | -8.46 Million USD | 11.36% |
| 2004 Q3 | -22.02 Million USD | 37.5% |
| 2004 Q2 | -35.23 Million USD | -316.27% |
| 2004 FY | -5.93 Million USD | 37.9% |
| 2004 Q4 | -5.93 Million USD | 73.07% |
| 2003 FY | -9.54 Million USD | 0.0% |
| 2003 Q4 | -9.54 Million USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | -31.519% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -333.738% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 168.361% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 524.651% |
| bluebird bio, Inc. | 108.57 Million USD | 224.711% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -1401.775% |
| Imunon, Inc. | -4.69 Million USD | -2781.297% |
| Editas Medicine, Inc. | -87.11 Million USD | -55.425% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 101.053% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 106.454% |
| Myriad Genetics, Inc. | 88.1 Million USD | 253.689% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 176.368% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -303.854% |
| Verastem, Inc. | -37.27 Million USD | -263.217% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.644% |
| Waters Corporation | 1.96 Billion USD | 106.907% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.504% |
| Biogen Inc. | 6.28 Billion USD | 102.153% |
| Nektar Therapeutics | 210.24 Million USD | 164.403% |
| Perrigo Company plc | 3.32 Billion USD | 104.076% |
| Dynavax Technologies Corporation | 106.63 Million USD | 226.975% |
| Illumina, Inc. | 1.21 Billion USD | 111.153% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 2043.148% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | -18.889% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 193.33% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1983.957% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 135.749% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -1807.042% |
| Evolus, Inc. | 63.7 Million USD | 312.532% |
| Adicet Bio, Inc. | -142 Million USD | 4.653% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -267.895% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -399.631% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 129.518% |
| FibroGen, Inc. | 56.76 Million USD | 338.519% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 111.825% |
| OPKO Health, Inc. | 230.68 Million USD | 158.695% |
| Homology Medicines, Inc. | 18.43 Million USD | 834.393% |
| Geron Corporation | 14.76 Million USD | 1017.282% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 108.541% |
| Exelixis, Inc. | -73.05 Million USD | -85.352% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -149.558% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 10.345% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -21.542% |
| Zoetis Inc. | 4.76 Billion USD | 102.843% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 32.239% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -1244.454% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 98.584% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -829.179% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 112.843% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 113.982% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 109.805% |
| Blueprint Medicines Corporation | 702.83 Million USD | 119.265% |
| Insmed Incorporated | 721.62 Million USD | 118.763% |
| TG Therapeutics, Inc. | 17.86 Million USD | 858.034% |
| Incyte Corporation | -3.17 Billion USD | 95.736% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 117.681% |